Rivaroxaban Viatris (previously Rivaroxaban Mylan)
Страна: Европейски съюз
Език: гръцки
Източник: EMA (European Medicines Agency)
Листовка
(PIL)
13-12-2023
Данни за продукта
(SPC)
13-12-2023
Доклад обществена оценка
(PAR)
29-11-2021
Активна съставка:
rivaroxaban
Предлага се от:
Mylan Ireland Limited
АТС код:
B01AF01
INN (Международно Name):
rivaroxaban
Терапевтична група:
Αντιθρομβωτικοί παράγοντες
Терапевтична област:
Venous Thromboembolism; Pulmonary Embolism; Acute Coronary Syndrome; Stroke; Coronary Artery Disease; Peripheral Arterial Disease; Atrial Fibrillation
Терапевтични показания:
Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. ------Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. -------Adults Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
Каталог на резюме:
Revision: 4
Статус Оторизация:
Εξουσιοδοτημένο
Дата Оторизация:
2021-11-12
Листовка
The website encountered an unexpected error. Please try again later.
Данни за продукта
The website encountered an unexpected error. Please try again later.
